Home > About > The Board

The Board

Oxtex has a very experienced Board of Directors and is further supported by a Scientific Advisory Board of internationally recognised academics and clinicians.
Nicholas Edwards (Chairman)

Nicholas Edwards - Oxtex ChairmanNicholas Edwards graduated in Physiological Sciences from The Queen’s College, Oxford in 1982 and then completed his training in Clinical Medicine (BM, BCh) at Oxford in 1985. After research into the use of Artificial Intelligence to perform medical diagnosis, he completed house jobs in Cardiology and General Surgery before joining Andersen Consulting in 1986. He spent 18 years with Andersen Consulting (now known as Accenture), including 8 years as a partner, and was the global leader of Accenture’s Pharmaceutical R&D business. In 2005, he was one of the founders of Kinapse, and MedInnovate. He is an investor and supporter of several life science start-ups. Nicholas is an Associate Fellow of Green Templeton College, Oxford and sits on their Development Committee. He is currently working on a Centre based within the University of Oxford developing better methods of translating medical innovations into useable treatments, with an initial focus on pharmaceutical R&D.

David Jackson (CEO)

David Jackson - Oxtex CEODavid is an experienced entrepreneur with over 25 years experience in early stage technology companies, he has a proven track record of taking early-stage opportunities through to exit. His last company, Site Intelligence Ltd is now a global player in the muti-channel customer analytics software market, supporting blue chip companies world-wide. Before that, he was part of the senior management team that took Oxford Molecular Group, one of the first Isis spin out companies, through to a main market listing in 1994 and becoming COO in 1996. Subsequently, he was the executive Chairman of FWPharma Systems Ltd, a management buyout company in clinical trials management software that was sold to Parexel inc in 2002. He was also a founder of Screen Science Ltd, a multi-media training company sold to the Adval group in 1998. David is also the Non-Executive Chairman of Brain in Hand Ltd, a company providing mobile device applications to help those with impaired executive brain function.

Jan Czernuszka (Technical Director)

Jan Czernuszka - Oxtex Technical DirectorJan Czernuszka is a University Lecturer at the University of Oxford and a Fellow of Trinity College. He is a Founding Scientist of Oxtex and its Chief Technical Officer. Jan set up and is Head of the Biomaterials Group at Oxford: this is now a Wellcome Trust Centre for Tissue Engineering. He has over 100 publications and nine patents and is regularly invited to give presentations at international conferences. He has been part of a group that obtained Oxford’s largest single grant of approximately £56m. Jan has been Dean and vice-President of Trinity College and is currently Chairman of the Faculty of Materials. He has a BSc (Hons) and ARSM from Imperial College, London, a Ph.D from the University of Cambridge and an M.A from the University of Oxford.

Marc Swan (Clinical Director)

Marc Swan - Oxtex Clinical DirectorMarc is a Consultant in Plastic and Reconstructive Surgery at the Oxford University Hospitals NHS Trust where he specialises in the treatment of orofacial clefting. He undertook his specialty training in Oxford and obtained the FRCS (Plast) in 2011. He has worked extensively overseas including the Red Cross Children’s Hospital in Cape Town, CoRSU Hospital in Kampala and the Comprehensive Cleft Care Centre in Guwahati. He undertook Fellowship training at The Hospital for Sick Children (Toronto, Canada) and Great Ormond Street Hospital (London, UK). The initial development of a self-inflating tissue expander was the motivation for his doctorate research undertaken jointly between the Nuffield Department of Surgery and the Department of Materials in the University of Oxford. He has since returned to full time NHS clinical practice although he maintains an active interest in the hydrogel research programme. Marc has authored over 50 scientific and medical papers, two patents, and is a contributor to the Oxford Handbook of Plastic Surgery.

David Stephens


david-stephens.jpgDavid Stephens has enjoyed roles in numerous businesses from early stage to listed companies. His background includes several years as the Chief Financial Officer of Dr. Solomon's Group plc, where he was involved in the management buy-out and initial public offerings of that company on NASDAQ and EASDAQ and the subsequent sale of the business to Network Associates in 1998 for $700m. Since the sale of Dr Solomon's, he has been an active investor and non-executive Director. This has included a major involvement in the sale of Content Technologies to Baltimore in 2001 for $1bn. David has a degree in Mathematics from St. Catherine's College, Oxford and is a Chartered Management Accountant.

Bryan Morton


bryan-morton.jpgBryan has over 30 years' experience as an entrepreneur and business leader in the life sciences industry. Most recently, he was Founder and Chief Executive of global oncology company EUSA Pharma, having raised $265 million from leading technology investors. The company was acquired by Jazz Pharmaceuticals in 2012 for $700 million. Prior to this, he founded and led Zeneus Pharma, a European specialty oncology and critical care company, which was subsequently acquired by Cephalon for $360 million. Previously, he was President of Convatec, EMEA (Bristol Myers Squibb), and prior to this he spent 20 years in positions of increasing seniority at Merck & Co. He currently is Chairman of Aircraft Medical, Energist, Oxford BioTherapeutics and ReNeuron and is a Non Executive Director on the Syncona LLP Board and Oxitec Board.

Chris Towler


chris_t.jpgChris Towler was educated in the life sciences, gaining a PhD in Biochemistry and undertaking a number of years of post-doctoral research in the area of onco-foetal antigens. He then spent 23 years in the Pharmaceutical Industry (Glaxo and GlaxoWellcome), 13 of which were as leader of a project management organisation within the Development Directorate, followed by a period as head of International and Manufacturing Regulatory Affairs. Chris led the development teams responsible for bringing a number of major novel therapies (including Imigran, Zofran and Relenza) to the market, served as a member of the Corporate Strategy Team and was closely involved with organisational change and post-merger integration projects.
In 2001, he joined Imperial College London to assist the new Vice Chancellor, Sir Richard Sykes, particularly in the realms of strategic planning, complex project management, commercialisation of science and communication. Chris joined Oxford University in 2008 as Director of Oxford Spinout Equity Management to create a new unit with responsibility for management of the University's shareholdings in its spinouts and investment of University funds in portfolio companies involved in a broad spectrum of technologies. Chris has experience of chairmanship or board membership of both science-based and property management companies.

Follow Oxtex

Enter your email address below.

What is tissue expansion?

A short explanation is available here.